A Study of Tetrathiomolybdate (TM) Plus Capecitabine

NCT06134375 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

204

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer
Residual Disease

Interventions

DRUG: Tetrathiomolybdate
DRUG: Capecitabine
DRUG: Pembrolizumab

Sponsor

Dartmouth-Hitchcock Medical Center

Collaborators

[object Object]
[object Object]